Long acting beta-2-agonists and their use as medicaments

Details Long acting beta-2-agonists and their use as medicaments Long acting beta-2-agonists and their use as medicaments

2008-05-20

2008-05-20

Habte, Kahsay T (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S071000, C544S074000, C544S092000, C544S105000

Reexamination Certificate

active

07375104

ABSTRACT:
A compound of formula 1′wherein:V is —CH2—, —NH—, or —O—;Raand Rbare each independently hydrogen, C1-4-alkyl, or halogen-C1-4-alkyl, orRaand Rbtogether are a C2-5-alkylene bridge wherein one or more hydrogen atoms are optionally replaced by halogen;R1and R1′are each independently hydrogen, C1-6-alkyl, C3-6-cycloalkyl, halogen-C1-6-alkyl, halogen-C3-6-cycloalkyl, or C1-6-alkylene-C3-6-cycloalkyl, orR1and R1′together are a C2-5-alkylene bridge wherein one or more hydrogen atoms are optionally replaced by halogen;R2, R2′, R2″, and R′″are each independently hydrogen, C1-6-alkyl, halogen-C1-6-alkylene, OH, HO—C1-6-alkylene, —O—C1-6-alkyl, C6-10-aryl, C6-10-aryl-C1-4-alkylene, C6-10-aryl-C1-6-alkylene-O, COOH, COOC1-6-alkyl, O—C1-6-alkylene-COOH, O—C1-6-alkylene-COOC1-6-alkyl, NHSO2—C1-6-alkyl, CN, NH2, NH—C1-6-alkyl, N(C1-6-alkyl)2, NO2, S—C1-6-alkyl, SO2—C1-6-alkyl, SO—C1-6-alkyl, O(CO)C1-6-alkyl, COC1-6-alkyl, NHCOC1-6-alkyl, or halogen; andn is 0, 1, or 2,or an optical isomer thereof, or a corresponding acid addition salt thereof with a pharmacologically acceptable acid, and the use thereof as pharmaceutical compositions, particularly for the treatment of inflammatory and obstructive respiratory complaints.

REFERENCES:
patent: 4215119 (1980-07-01), Mentrup et al.
patent: 4341778 (1982-07-01), Mentrup et al.
patent: 6951888 (2005-10-01), Buettner et al.
patent: 7056916 (2006-06-01), Konetzki et al.
patent: 7135500 (2006-11-01), Konetzki et al.
patent: 7244728 (2007-07-01), Bouyssou et al.
patent: 2002/0022625 (2002-02-01), Schromm et al.
patent: 2004/0122108 (2004-06-01), Bouyssou et al.
patent: 2004/0147513 (2004-07-01), Bouyssou et al.
patent: 2005/0197374 (2005-09-01), Bouyssou et al.
patent: 2005/0234112 (2005-10-01), Bouyssou et al.
patent: 2 405 745 (2001-11-01), None
patent: 0043940 (1981-06-01), None
patent: WO 01/83462 (2001-11-01), None
U.S. Appl. No. 09/836,462, filed Apr. 18, 2001, K. Bozung et al.
U.S. Appl. No. 10/697,525, filed Oct. 30, 2003, T. Bouyssou et al.
U.S. Appl. No. 11/028,264, filed Jan. 3, 2005, T. Bouyssou et al.
U.S. Appl. No. 11/057,893, filed Feb. 14, 2005, T. Bouyssou et al.
U.S. Appl. No. 11/074,263, filed Mar. 7, 2005, T. Bouyssou et al.
Kriton Iakovou, et al, “Systhesis of oxypropanolamine derivatives of 3,4-dihydro-2H-1,4-benzoxazine, beta-adrenergic affinity, inotropic chronotropic and coronary vasodilating activities” ′Eur. J. Med. Chem. 34, 1999. pp. 903-917.
International Search Report for PCT/EP2005/000245 mailed May 11, 2005.

Affiliated with

Also associated with

Rating

Long acting beta-2-agonists and their use as medicaments does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Long acting beta-2-agonists and their use as medicaments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Long acting beta-2-agonists and their use as medicaments will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2769010